光疗对Demodex密度的影响:一个病例对照研究
Hasan Aksoy1, Melek Aslan Kayıran1, Yeşim Dede1
1Department of Dermatology, Istanbul Medeniyet University Prof. Dr. Suleyman Yalcin City Hospital, İstanbul, Turkey.
International journal of dermatology
|January 18, 2024
概括
光疗并没有显著改变正在接受治疗的患者的Demodex虫密度或demodicosis的流行率. 这项研究表明,先前的发现,将光疗与增加的Demodex感染联系起来,可能需要进一步调查.
科学领域:
- 皮肤病学 皮肤病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 人类的Demodex虫 (Demodex folliculorum和Demodex brevis) 在无症状的情况下居住在pilosebaceous单位.
- 以前的研究表明,光疗和痴呆症之间存在联系.
- 目前的研究调查了光疗对Demodex密度和demodicosis流行率的影响.
研究的目的:
- 为了确定20次光疗会是否会增加Demodex密度.
- 为了评估光疗是否会影响demodicosis的频率.
- 评估光疗与Demodex虫感染之间的关系.
主要方法:
- 一项病例控制研究涉及32名参与者,接受了窄带紫外线B或紫外线A-1治疗.
- 标准化皮肤表面活检被用于测量20次光疗疗程前后的Demodex密度.
- 评估了与demodex相关的皮肤状况,统计分析比较了治疗前后的demodex密度和demodicosis患病率.
主要成果:
- 在20次光疗疗程 (2.75±4.48/cm2治疗前与2.85±4.81/cm2治疗后;P=0.879) 后,没有观察到Demodex密度的统计学意义上的变化.
- 痴呆症的患病率在基线 (28.1%) 和治疗后 (31.3%) (P=1.00) 之间没有显著差异.
- 这些发现与之前关于光疗后增加Demodex密度和demodicosis的建议相矛盾.
结论:
- 该研究的结果不支持光疗与增加的Demodex密度或demodicosis之间的联系.
- 由于方法上的局限性,关于光疗诱导的免疫抑制和Demodex感染的先前研究结论仍在争论中.
- 建议使用同质样本进行更大规模的纵向研究,以澄清光疗-脱毛症的关系.
相关概念视频
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.